Mayne Pharma and GoodRx Announce New Initiative to Increase Awareness of NEXTSTELLIS®
Mayne Pharma Group Limited is pleased to announce a new strategic collaboration with GoodRx, a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States. In addition, the initiative is focused on improving access to and raising awareness of available birth control methods.
GoodRx has millions of visitors who come to the site each month looking for ways to save on their medications and more than 750,000 healthcare providers (HCPs) have used the platform since June 2021 to help their patients access their prescriptions. By combining GoodRx's reach with Mayne Pharma's novel contraceptive, which IQVIA notes is the fastest growing branded contraceptive in 2022 based on total prescriptions dispensed[1], this program will help further engage consumers and increase access for NEXTSTELLIS®. It will also build awareness among HCPs, over 4,000 of whom have already written prescriptions for the product.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
